CLINICAL TRIALS PROFILE FOR TAMOXIFEN CITRATE
✉ Email this page to a colleague
All Clinical Trials for TAMOXIFEN CITRATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002460 ↗ | Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer | Unknown status | Cancer Research UK | Phase 3 | 1987-09-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. PURPOSE: Phase III trial to compare the effectiveness of adjuvant therapy using tamoxifen or ovarian ablation with goserelin or both in treating women with stage I or stage II breast cancer. |
| NCT00002528 ↗ | Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer | Completed | International Breast Cancer Study Group | Phase 3 | 1993-05-01 | RATIONALE: Removing axillary lymph nodes may be effective in stopping the spread of breast cancer cells. It is not yet known if surgery to remove breast cancer is more effective with or without lymph node removal. PURPOSE: Randomized phase III trial to compare the effectiveness of breast surgery with or without removal of axillary lymph nodes in treating women who have stage I or stage IIA breast cancer. |
| NCT00002529 ↗ | Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer | Completed | International Breast Cancer Study Group | Phase 3 | 1993-05-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy during or after combination chemotherapy or hormone therapy alone in treating perimenopausal or postmenopausal women who have stage II or stage IIIA breast cancer. |
| NCT00002542 ↗ | Tamoxifen in Treating Women With High-Risk Breast Cancer | Completed | NCIC Clinical Trials Group | Phase 3 | 1993-07-20 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to study the effectiveness of tamoxifen following surgery and chemotherapy in treating women who have stage I breast cancer at high risk of recurrence or stage II or stage III breast cancer. |
| NCT00002579 ↗ | Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer | Completed | Scottish Cancer Therapy Network | Phase 3 | 1993-03-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining combination chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without tamoxifen in treating women with stage I or stage II breast cancer that can be surgically removed. |
| NCT00002580 ↗ | Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer | Completed | Scottish Cancer Therapy Network | Phase 3 | 1993-06-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with that of ovarian ablation, and/or combination chemotherapy in treating premenopausal women with stage I, stage II, or stage IIIA breast cancer. |
| NCT00002581 ↗ | Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer | Completed | Scottish Cancer Therapy Network | Phase 3 | 1993-06-01 | RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining combination chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without combination chemotherapy in treating postmenopausal women with stage I or stage II breast cancer that can be surgically removed. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TAMOXIFEN CITRATE
Condition Name
Clinical Trial Locations for TAMOXIFEN CITRATE
Trials by Country
Clinical Trial Progress for TAMOXIFEN CITRATE
Clinical Trial Phase
Clinical Trial Sponsors for TAMOXIFEN CITRATE
Sponsor Name
